Compare Abeona Therapeutics Inc (ABEO) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs IQIYI Inc - ADR — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while IQIYI Inc - ADR trades at $1.07 (market cap $960.59M). The key difference: IQIYI Inc - ADR is far larger — about 2.6× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals.
| ABEO | IQ | |
|---|---|---|
Market Cap | $373.32M | $960.59M |
Sector | Health | Media |
52-Week High | $7.23 | $2.79 |
52-Week Low | $4.17 | $0.96 |
Enterprise Value | $228.22M | $2.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
iQIYI (IQ) trades at $0.9954, down 1.45% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $206.31 million in 2025 despite $27.29 billion in revenue, with negative profit margins and declining revenue trends. Recent news highlights leadership changes and AI platform expansion, but financial performance remains pressured.
The outlook is mixed: analyst consensus leans bullish with 50% buy ratings, but fundamental weakness and cash flow volatility pose risks. Investment opportunity hinges on AI-driven turnaround execution, while key risks include sustained profitability challenges and competitive pressures in China's streaming market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
